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Abstract: Transfusion of blood components is widely 
utilized in the management of medical and surgical 
conditions. Though transfusion is a life-saving 
intervention, there has been debate about the 
standardization of blood transfusion practices. There has 
been a tremendous response in literature generated from 
multiple medical specialties regarding appropriate use of 
blood products to guide clinicians in their transfusion 
decisions. However, the consequence of numerous 
guidelines from multiple specialties results in varying 
recommendations for transfusion practices. This study 
was designed to compare and analyze current guidelines 
to determine if the recommendations generated to guide 
clinicians in transfusion decisions are truly supported by 
quality evidence. We performed a literature search on 
clinical transfusion practice guidelines from January 
2005 to October 2015 with the following computer 
databases: PubMed/Medline, Cochrane Central, Scopus 
and the National Guideline Clearinghouse. Additional 
websites and publications, such as the Australian and 
New Zealand Society of Blood Transfusion, were also 
searched for guidelines missed from the computer 
database search. Key words that were used for the search 
include the combination of the following keywords: 
blood, blood component, blood product, transfusion, 
guidelines. The resulting eleven guidelines were 
analyzed for the following areas: characteristics and 
composition of the guideline working group panel, 
literature and evidence utilized for the systematic review, 
databases utilized to retrieve evidence and literature for 
the systematic review, methodologies employed by 
guideline committees to grade strength and quality of 
evidence and recommendations, quantity of 
recommendations suggested, and specific transfusion 
thresholds and/or clinical settings for transfusion of 
blood products. We developed a three-tiered 
classification system in order to compare the level of 
evidence and strength of recommendations generated by 
each guideline even with the utilization of seven 
difference grading systems. A total of 107 
recommendations were generated about packed red blood 
cells, fresh frozen plasma, platelets, and cryoprecipitate 
transfusion. Of the 107 recommendations, 48 (48.86%) 
of the recommendations were specific to the use of 
packed red blood cells, 31 (28.97%) of the 
recommendations were specific to the use of fresh frozen 
plasma, 15 (12.02%) of the recommendations were 
specific for the use of platelets, and only 13 (12.15% 
recommendations were specific to the use of 
cryoprecipitate. Future research should thus be 
stimulated and directed at providing more abundant and 
high quality evidence regarding the use and safety of 
blood components in the perioperative setting. 
Keywords: Health and environmental sciences; 
Biopractice guideline; Blood components; Blood 
platelets; Blood transfusions; Evidence-based 
medicine 
 
Background 
Transfusion of blood components is 
widely utilized in the management of medical and 
surgical conditions. With the discovery of blood 
types and advancements in medicine, transfusion 
can be a life-saving intervention. One of the most 
important reasons for red blood cell (RBC) 
transfusion is to restore, or maintain, oxygen 
delivery to vital organs in the human body. Fresh 
frozen plasma (FFP) transfusion is utilized to treat 
coagulopathies, life threatening bleeding diathesis 
and reverse effects of warfarin. Cryoprecipitate is 
indicated for the treatment of von Willebrand’s 
disease, Hemophilia A, Factor XIII deficiency and 
hypofibrinogenemia, especially when recombinant 
products are not available. In 2003, the National 
Blood Data Resource Center estimated that 14 
million units of whole blood were collected, 
processed into 27 million units of blood products 
and subsequently transfused in to 4.5 million 
medical and surgical patients.
1
 though transfusion 
is a life-saving intervention, there is continuing 
debate about the standardization of blood 
transfusion practices. Not only has blood become a 
scarce resource in a large growing population, but 
transfusion of blood and blood products also carry 
significant risks. 
Oxygen is carried in red blood cells 
and reversibly bound to the tetramer 
hemoglobin. Adequate oxygenation of the 
tissues is dependent on the balance of oxygen 
consumption and oxygen delivery. Oxygen 
consumption can remain constant over a wide 
range of oxygen delivery. However as oxygen 
delivery reaches a critical threshold, tissue 
extraction of oxygen cannot be further 
increased to meet the metabolic needs of the 
tissue. Oxygen delivery below the critical 
threshold results in the beginning of anaerobic 
metabolism and the production of substrates 
such as lactate, nicotinamide adenine 
dinucleotide (NADH), and reduced 
cytochrome oxidase. This critical threshold of 
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oxygen delivery occurs at different levels in 
different organ systems. The critical threshold 
is dependent on the regional and global blood 
flow regulation, as well as the metabolic needs 
of the organs. 
Oxygen delivery (DO2) to the whole body is 
dependent on the relationship between cardiac 
output (CO) and oxygen content (CaO2) in the 
arterial blood [equation 1].  
Oxygen consumption (VO2) in the whole body is 
dependent on cardiac output and the oxygen 
content difference between arterial (CaO2) and 
venous blood (CvO2) [equation 2]. 
DO2 = CO × CaO2 (normal range: 460 to 650 
mL/min/m
2
) 
[equation 1] 
 
VO2= CO × (CaO2– CvO2) (normal range: 96 to 
170 mL/min/m
2
) 
[equation 2] 
Where: 
CaO2 = (Hb × 1.39 × SaO2) + (0.003 × PaO2) 
CvO2 = (Hb × 1.39 × SvO2) + (0.003 × PvO2) 
Hb, hemoglobin; SaO2, arterial oxygen saturation; 
PaO2, arterial oxygen tension; SvO2 mixed venous 
oxygen saturation; PvO2, mixed-venous oxygen 
tension 
Reduction in whole body oxygen delivery 
can therefore result from either, decrease in cardiac 
output, or decrease in arterial blood oxygen content 
(profound anemia, massive hemorrhage, 
hypoxemia, and decrease in oxygen saturation). In 
addition to cardiac output and arterial blood oxygen 
content influencing whole body oxygen delivery, 
microvascular capillary regulatory mechanisms can 
also affect tissue oxygen delivery. Functional 
physiologic shunting can decrease tissue oxygen 
delivery, while pharmacologic manipulation of 
microvasculature can increase tissue oxygen 
delivery.
2  
Theoretically, red blood cell transfusion is 
capable of enhancing arterial blood oxygen content, 
and thereby increasing total whole body oxygen 
delivery. However the use of red blood cell 
transfusion to manipulate and potentially increase 
tissue oxygen delivery is complex and its efficacy 
is not completely clear.
3-7
 Transfusion increases 
hemoglobin levels (hence increase in oxygen 
content) and in cases where there is a reduction of 
preload, transfusion can additionally increase 
cardiac output and thus total body oxygen delivery. 
However, increasing hemoglobin levels and 
oxygen content via transfusion may not lead to the 
immediate desired result of increase oxygen 
delivery at the tissue level.
8-12
 The transfusion of 
stored red blood cells can trigger biochemical and 
inflammatory reactions and potentially result in 
decreased oxygen delivery at the tissue level.
8-12 
Fresh frozen plasma is one of the least 
understood blood products. It contains albumin, 
globulins, fibrinogen and other coagulation factors. 
Even though it has limited recommendations for its 
use, it is most often used to treat bleeding disorders 
when a coagulation factor or multiple coagulation 
factors are deficient or no coagulation factor- 
specific concentrate is available.
13
  Recommended 
uses for fresh frozen plasma are listed in table 1. 
Fresh frozen plasma is the most frequently misused 
blood product.
14,15 
 
Table 1. Recommended uses for FFP 
 
Single coagulation factor deficiencies 
Multiple coagulation factor deficiencies with severe bleeding in disseminated intravascular coagulation 
(DIC) 
Thrombotic thrombocytopenic purpura (TTP) 
Reversal of warfarin effect 
Surgical bleeding and hemostasis  
Hemorrhagic disease of the newborn 
Neonates with coagulopathy and in need for a surgical procedureRed cell T antigen in newborns  
 
Cryoprecipitate is the portion of the plasma that is 
rich in coagulation factors, including factor VIII, 
fibrinogen, von Willebrand factor and factor XIII.
13
 
Cryoprecipiate is used primarily for the reversal of 
hypofibrinogenemia caused by massive transfusion 
or disseminated intravascular coagulation (DIC). It 
is also considered for use in treatment of von 
Willenbrand’s disease, Hemophila A, and Factor 
XIII deficiency when recombinant products are not 
available. 
 
Platelets are administered to treat either 
thrombocytopenia or provide functional platelets. 
Thrombocytopenia, a decrease in number of 
circulating platelets, is caused by either an 
increased destruction (idiopathic, 
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immunologically-mediated, DIC) or decreased 
production of platelets (myelosuppressive drugs, 
radiation, chronic alcohol use). 
 
Blood component therapy can be 
potentially life-saving and at the same time can 
have deleterious effects. Thus transfusion of blood 
products should not be taken lightly. Ideally blood 
product should only be transfused when necessary. 
If clinicians could easily monitor for optimal 
oxygen delivery and coagulation status, blood 
product transfusions could be optimized. However, 
in rapidly changing clinical situations, it is 
challenging to predict the need for blood products 
precisely. With this in mind, transfusion triggers or 
thresholds based on measurable physiological 
parameters, could aid and guide clinicians in 
making the decision for transfusion therapy. It is 
expected that these transfusion thresholds are 
developed from quality evidence and based on 
rigorous clinical trials and studies that demonstrate 
improvement in patient outcomes. 
 
History of Perioperative Transfusion 
 
There is significant variability in 
transfusion practices among the different medical 
specialties. Historically, a hemoglobin of 10 g/dL 
and a hemotocrit of 30% were widely used and 
accepted as “transfusion triggers” for red blood cell 
transfusion particularly in the surgical setting.
16
 In 
the 1970s, red blood cells were often times 
withheld until symptoms of anemia developed or 
there was a clinically significant drop of <10 g/dL 
in hemoglobin.
17-19
 In 1988 the National Heart, 
Lung and Blood institute, the Office of Medical 
Applications of Research, the Warren Grant 
Magnuson Clinical Center of the National Institute 
of Health, and the Food and Drug Administration 
convened the Consensus Development Conference 
on Perioperative Red Cell Transfusion to discuss 
the criteria for perioperative red blood cell 
transfusion, the morbidity of anemia in the 
perioperative period, and immediate and long-term 
risks of transfusion. This consensus conference 
concluded that available evidence at the time did 
not support a single criterion for red blood cell 
transfusion, mild-moderate anemia did not 
contribute to perioperative morbidity, and 
transfusions should be kept to a minimum due to 
the documented risks of infection and deleterious 
immune modulation.
20
 The consensus conference 
concluded that future research was necessary to 
define the best indications for perioperative red 
blood cell transfusion. 
 
Different authors have suggested a range of 
hemoglobin levels as criterion for transfusion (6.0-
10.0g/dL), depending on the presence of several 
co-morbidities.
21-23
 In 1999, the Canadian Critical 
Care Trials Group demonstrated that a restrictive 
strategy of red blood cell transfusion in 838 
critically ill patients reduced hospitalization 
mortality rates in a multicenter, randomized 
controlled clinical trial referred to as the 
Transfusion Requirements in Critical Care 
(TRICC) trial.
24
 Except in patients with acute 
myocardial infarction and unstable angina, a 
restrictive transfusion strategy (threshold of 
hemoglobin 7.0g/dL; hemoglobin range of 7.0-
9.0g/dL) was as effective, if not significantly better 
at lowering hospital mortality rates, than a liberal 
transfusion strategy (hemoglobin threshold of 
10.0g/dL; hemoglobin range of 10.0-12.0g/dL). 
 
In 2001, a randomized controlled clinical 
trial was performed to determine if a low 
transfusion threshold was safe in critically ill 
patients with known cardiovascular disease.
25
 This 
study concluded that there was no difference in 
mortality or myocardial infarction rates in the 
restrictive (transfusion threshold of hemoglobin 
7.0g/dL; hemoglobin range 7.0 - 9.0g/dL) versus 
liberal (transfusion threshold of haemoglobin 
10.0g/dL; hemoglobin range 10.0 - 12.0g/dL) 
transfusion groups.
25
 However, it suggested that a 
restrictive transfusion strategy appeared to be safe 
in most patients with cardiovascular disease, with 
the exception of patients with acute myocardial 
infarcts and unstable angina. On the contrary, in 
other studies, in patients undergoing coronary 
artery bypass graft surgery or myocardial 
revascularization there was no difference in 
mortality rates when a restrictive (hemoglobin 
8.0g/dL) transfusion 
threshold was compared to a liberal (9.0g/dL) 
transfusion threshold.
26,27
 
 
In contrast to packed red blood cells, there 
is little data on the relationship of transfusion of 
coagulation blood products, such as platelets, fresh 
frozen plasma, cryoprecipitate, and patient 
outcomes. Of the coagulation blood products 
mentioned, there are more data about the 
transfusion of platelets in the perioperative period. 
In 2004, a study with 1,720 patients who received 
platelet transfusion, suggested a significant 
association between platelet transfusion and the 
risk of infection, stroke and 
 
death.
28
 There have been no prospective 
randomized trials to date investigating the liberal 
or prophylactic use of platelet transfusion and its 
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association with increased rate of stroke and death. 
Moreover, there is limited data from randomized 
controlled trials regarding the threshold for 
transfusion of fresh frozen plasma and 
cryoprecipitate, and patient outcomes. 
 
Risks of Blood Product Transfusion 
 
More than twenty years ago, blood and 
blood component transfusion were thought to be 
relatively safe. Then in the 1980s, up to 1 in 100 
blood units was found to transmit the human 
immunodeficiency virus (HIV) or hepatitis C 
 
virus (HCV), as plasma did not undergo viral 
inactivation.
29
 There have been significant 
advancements in transfusion medicine in the past 
30 years, such as nucleic-acid testing, that have 
reduced the estimated residual risk of infection 
with the HIV or HCV to 1 in 1.5 million to 1 in 2 
million units transfused.
30
 Current risk of 
transmission of blood-borne viruses are listed in 
table 2.
31 
 
Table 2. Contemporary risk of transmitting any of the blood-borne viruses.
31
 
 
Virus  Risk per Unit Transmission  Window 
 Transfusion  Rate Period 
Human Immunodeficiency 1:2,135,000 90% 11 days 
Virus 1&2    
Hepatitis C Virus  1:1,935,000 90% 10 days 
Hepatitis B Virus  1:205 ,0 00 70% 59 days 
Human T-lymphotrophic 1:3,000,000 30% 51 days 
Virus     
West Nile Virus  1:10,000 to 1,000* unkno w n - 
Parvovirus B19 1:40,000 to 3,000 low - 
Hepatitis A/E 1:1,000,000 low - 
*prior to nucleic acid testing    
 
Emerging infections, defined as those 
infections whose incidence in humans has 
increased within the past two decades or threatens 
to increase in the near future, may have an 
asymptomatic blood-borne phase and may exist 
and can be transmittable by transfusion. Current 
infectious agents that are emerging to threaten 
blood and blood component safety include, but are 
not limited to, are: human variant Creuztfeld-Jakob 
disease, West Nile virus, Babesia species, GB virus 
C-hepatitis G virus, SEN virus, TT 
virus, human herpesvirus 8, and simian foamy 
virus.
32-34
 
 
Though transmission of infection by 
blood transfusion has decreased significantly, 
transfusion-related acute lung injury (TRALI) has 
now become the leading cause of transfusion 
related mortality. Fresh frozen plasma 
administration has been shown to be an 
independent risk factor for TRALI in trauma, 
medical and surgical ICU patient.
35
 Intensive care 
unit patients, enrolled in the 2004 CRIT (Anemia 
and Blood Transfusion in CRITical Care) study, 
who received red blood cell transfusions, 
experienced a higher incidence of overall 
complications. The study demonstrated that the 
number of red blood cell transfusions a patient 
received was independently associated with a 
longer ICU stay, length of hospital stay, and 
 
increase in mortality.
36
 With these current 
transfusion risks in mind, practitioners are relying 
heavily on transfusion practice guidelines and 
recommendations. The goal of these clinical 
transfusion practice guidelines and 
recommendations is to limit unnecessary 
transfusion of blood products, improve blood 
component transfusion therapy for patients and 
hopefully improve clinical outcomes. 
 
History of the Development of Transfusion 
Guidelines  
 
The development of guidelines were 
proposed in 1990 by the Institute of Medicine to 
reduce inappropriate health care variation by aiding 
physician decision- making.
37
 Decision-making in 
healthcare should acknowledge benefits and risks 
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of medical interventions, as well as the underlying 
quality of evidence to support such interventions. 
 
The number of practice guidelines  has 
mushroomed significantly, with each of the 
medical societies developing their own set of 
guidelines for areas of interest for them. 
38
 A 
variety of medical specialties have published 
recommendations, on the use of blood products, to 
guide clinicians in their transfusion decisions. In 
the 1980s, the National Institute of Medicine held 
consensus conferences on the use of red blood 
cells, fresh frozen plasma, and platelets.
39-41
 In the 
1990s, the American College of Physicians and 
American College of Pathologists issued guidelines 
regarding red blood cell and fresh frozen plasma, 
cryoprecipitate and platelet transfusion 
respectively.
42,43
 The American Association of 
Blood Banks also generated guidelines regarding 
transfusion during coronary artery bypass graft 
surgery and appropriate blood utilization.
44,45
 In the 
same decade, the American Society of 
Anesthesiologists (ASA) developed a Task Force 
to develop guidelines regarding blood component 
therapy.
46
 However, the consequence of numerous 
guidelines from multiple specialties results in 
varying recommendations for each intervention, 
which can be confusing for physicians. 
Furthermore, when several physicians are involved 
in the care of a patient, their decisions when to 
transfuse can differ significantly, based on what 
guideline the care-giver is following. 
 
Guidelines for physicians should comprise 
of the following: the scope of the practice 
guidelines, current interventions and practices 
considered, strength of recommendations and the 
quality of used evidence. The recommendations 
developed in guidelines ideally should be based on 
strong evidence. However in actuality, guidelines 
may generate strong recommendations on 
consensus expert opinions rather than on high 
quality evidence.
37
 In addition, these guidelines use 
multiple systems to grade the quality of evidence, 
as well as to classify the strength of their 
recommendations. Thus, it is important to compare 
and analyze current guidelines, to determine 
variations in recommendations and if the 
recommendations generated to guide clinicians are 
truly supported by quality evidence. In addition, it 
is also important to consider and evaluate 
guidelines for the composition of their working 
group, types of studies used to develop guidelines, 
and the specific methodologies utilized to grade 
evidence and classify recommendations. In this 
study, we compared different guidelines for 
variations in guideline development, 
recommendations and their level of evidence. 
 
Methods  
A comprehensive literature search on 
clinical transfusion guidelines of blood 
components was identified and performed using 
the following computer databases: 
PubMed/Medline, Cochrane Central, Scopus and 
the National Guideline Clearinghouse. Additional 
websites and publications of relevant scientific 
societies, such as the Australian and New Zealand 
Society of Blood Transfusion, were also searched 
for guidelines missed from the computer database 
search. Key words that were used for searching the 
databases include the combination of the following 
keywords: blood, blood component, blood product, 
transfusion, guidelines. Of those database searches 
of articles, only articles from January 2005 to 
October 2015 written in the English language were 
retrieved. The articles/guidelines were limited to 
the last 5 years as we assumed that the literature 
within that time frame was most current and 
clinically relevant. However some guidelines 
outside of this time period were included, in order 
to provide complete representation of guideline 
recommendations from countries  not represented in 
the initial computer database searches. In these 
cases, only the most current practice guideline 
published from the societies were utilized. 
Relevance of the articles to be retrieved was 
evaluated and included if there were clear 
transfusion indications and recommendations 
stated within the article. Articles regarding 
transfusion practices in children or neonates were 
not included in this study. A total of eleven 
international guidelines were included in this study 
for final analysis ranging from the year 2001 to 
2015. 
The resulting eleven guidelines were 
analyzed for the following areas: characteristics 
and composition of the guideline working group 
panel, literature and evidence utilized for the 
systematic review, databases utilized to retrieve 
evidence and literature for the systematic review, 
methodologies employed by guideline committees 
to grade strength and quality of evidence and 
recommendations, quantity of recommendations 
suggested, and specific transfusion thresholds 
and/or clinical settings for transfusion of blood 
products. 
 
The eleven guidelines use seven different 
systems to grade the strength of recommendations 
and the level of evidence. In order to help us 
compare the level of evidence and strength of 
recommendations amongst these guidelines, we 
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developed a three-tiered classification system for 
both grading level of evidence and strength of 
recommendation (Table 2 and 3). This system was 
applied to all eleven guidelines reviewed. The 
terms “strong,” “intermediate,” and “low” level of 
evidence as used in this study are described and 
defined in table 3. The terms “strong,” 
“intermediate,” and “low” grade of 
recommendation as used in this study are described 
and defined table 4. 
 Table 3. Compilation of Level of Evidence Grading     
           
 Grading of GRADE AHRQ USPSTF  USPSTF AHA/ACC NHMRC ASA  
 Evidence   (After  (Before     
    May  May     
    2007)  2007)     
 STRONG High/A 1A High  Good A I Support  
    (Class I)       
   1B     II   
 
INTERMEDIA
TE Moderate/B 2A Moderate  Fair B III1 Suggest  
    (Class II)       
   2B     III2   
 LOW Low /C 3 Low  Poor C III3 Equivocal  
    (Class III)       
  Very Low /D 4     IV Silent             
         Insufficient  
         Inadequate  
 
GRADE = Grading of Recommendations, Assessment, 
Development, and Evaluation     
 
USPSTF = U.S. Preventative 
Task Force         
 
ACC/AHA = American College of Cardiology/American 
Heart Association      
 
ASA = American Society of 
Anesthesiologists         
 
NHMRC = Australian National Health and Medical 
Research Council      
 
ARHQ = Agency for Healthcare Research 
and Quality        
Table 4. Compilation Strength of Recommendation Classification 
 
Strength of GRADE AHRQ USPSTF USPSTF AHA/ACC NHMRC ASA 
Recommendation   (After (Before    
   May May    
   2007) 2007)    
STRONG Strong  A (Level A Class I A Strongly 
 (1)  1)    agree 
    B   Agree 
INTERMEDIATE   B (Level C Class IIa B Equivocal 
   2)     
   C  Class IIb   
WEAK Weak  D (Level D Class III C Disagree 
 (2)  3)     
   I I  D Strongly 
       disagree 
GRADE = Grading of Recommendations, Assessment, Development, 
and Evaluation    
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USPSTF = U.S. Preventative 
Task Force       
ACC/AHA = American College of Cardiology/American Heart 
Association    
ASA = American Society of 
Anesthesiologists       
NHMRC = Australian National Health and Medical 
Research Council     
ARHQ = Agency for Healthcare Research 
and Quality      
Results  
The bibliographic search conducted was limited to articles written in the English language p ublished 
during the period from January 2005 to October 2015. A comprehensive literature search to identify guidelines 
relevant to transfusion of blood components was performed and yielded the following results: PubMed/Medline 
(701), Cochrane Central (38), Scopus (4,292), and the National Guidelines Clearinghouse (2,073). Additional 
publications from relevant scientific societies, such as the Australian and New Zealand Society of Blood 
Transfusion, were also searched to identify guidelines missed from the database screen. An initial screening of 
these references identified potentially relevant articles. The final analysis of these articles resulted in the 
identification of 11 international guidelines addressing clinical transfusion practices of blood compone nts. 
 
Guidelines Working Group Panel Composition 
Table 5 and figure 1 report the panel composition of working groups for each of the eleven guidelines. 
To address the composition of working groups that prepared guidelines we looked at the number of total 
members, medical specialties represented, international/national societies represented, and consulting 
methodologists involved in the working group panels. Six of eleven guidelines reported the number of medical 
specialties represented by each panel member. However, only five guidelines detailed the number of 
international/national medical societies represented by each panel member. Similarly, five of eleven guidelines 
reported the total number of members composed their working group. Only two of eleven guidelines reported 
involving consultant methodologists in the working group panel. 
 
Table 5. Working Group Panel Composition 
Author Number of Number of Number of Number of 
 members specialties societies consulting 
  represented represented methodologists 
     
Roback et al (2010) 17 6 (9 members) 6 3 
     
Napolitano et al NM 5 2 NM 
(2009)     
     
Dellinger et al (2008) 55 NM 16 NM 
     
Ferraris et al (2007) 17 NM NM NM 
     
Spahn et al (2007) NM 5 5 NM 
     
Stainsby et al (2006) 100 NM 3 NM 
     
Wong et al (2007) NM 2 NM NM 
     
Droubatchevskaia et NM 3 NM NM 
al (2007)     
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Author Number of Number of Number of Number of 
 members specialties societies consulting 
  represented represented methodologists 
     
ASA Task Force 10 4 NM 2 
(2006)     
     
New Zealand (2001) NM 3 NM NM 
     
Cochrane (2009) NM NM NM NM 
     
(“NM “ indicates not mentioned)     
 
Figure 1. Number of Members in Working Group Panel  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6 and figure 2 report the number of 
medical specialties represented in each working 
group panel for the eleven guidelines. Six of the 
eleven guidelines reported having a panel member 
specialized in internal medicine and/or critical care 
medicine. Five of the eleven guidelines reported 
having a panel member specialized in hematology, 
anesthesiology, or surgery. Within the guidelines 
mentioning a panel member specializing in 
surgery, three specified having a member from 
trauma and/or thoracic surgery. Three of the eleven 
guidelines also reported having a panel member 
specialized in pathology. Pediatrics, obstetrics, 
transfusion pathology, oncology, transfusion 
medicine were mentioned to be represented in only 
one of the guidelines. 
 
One of eleven guidelines reported five medical 
specialties represented, three of eleven guidelines 
reported four medical specialties represented, one 
of eleven guidelines reported three medical 
specialties represented, two of eleven guidelines 
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reported two medical specialties represented, and 
two of eleven guidelines reported only one medical 
specialty represented in the working group panel. 
Emergency medicine, pediatrics and obstetrics 
specialties were reported in the working group 
panel of only one guideline. Orthopedic surgery, 
vascular surgery, oncologic surgery, solid organ 
transplant surgery and neurosurgery were not 
represented (or mentioned) in any of the eleven 
guidelines. 
 
Table 6. Medical Specialties Represented in Working Group Panel 
 
Author 
Hematolo
gy Patho log y 
Anesthesiol
ogy Internal 
Emergenc
y Pedia t rics Surge ry 
Obstetric
s Total 
    
Medicine/
Cri Medicine  (Thor a cic/  
Number 
of 
    tical Care   Trau m a )  
Specialtie
s 
          
Roback et al X (9) X (9) X(2) X (4) NM X(2) NM NM 5 
(2010)          
          
Napolitano NM NM NM X (?) NM NM 
X 
(?/Trauma) NM 2 
et al (2009)          
          
Dellinger et NM NM NM X (?) NM NM NM NM 1 
al (2008)          
          
Ferraris et NM NM X NM NM NM 
X 
(Thoracic) NM 2 
al (2007)          
          
Spahn et al X NM NM X X NM 
X 
(?/Trauma) NM 4 
(2007)          
          
Stainsby et X NM NM NM NM NM NM NM 1 
al (2006)          
          
Wong et al X X X X NM NM NM NM 3 
(2007)    
(Transfusi
on)      
          
Droubhatch X X NM X NM NM NM NM 3 
evskaia et          
al (2007)          
          
ASA Task NM X X NM NM NM X X 4 
Force  
(Transfusi
on)        
(2006)          
New X NM X 
X 
(Oncology
) NM NM X NM 4 
Zealand          
(2001)          
Cochrane NM NM NM NM NM NM NM NM NM 
(2009)          
 
       11  
161 
Asian Journal of Multidisciplinary Studies, 5(11) November, 2017 
 
  
  
 
 
 
Figure 2. Number of Medical and Surgical Specialties Represented  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Evidence and Systematic Reviews Utilized to Generate Guidelines  
 
Table 7 demonstrates the study design of the evidence utilized in the development of the eleven 
guidelines. Four of the eleven guidelines reviewed listed detailed methods of their literature review and their 
study design of the literature searched and reviewed. One guideline only mentioned the study designs they 
excluded from their literature search. Five of eleven guidelines analyzed in this study did not reveal the study 
designs of the literature they utilized in their search and in the development of their guidelines.  
            
 Table 7. Systematic review: Study Design of Evidence Utilized    
            
 Author 
Randomiz
ed  Case Case 
Observatio
nal 
Systemati
c Meta- 
Guideline
s 
Abstract
s 
Editori
als  
  Controlled  Control Reports   Reviews analysis     
  Trials           
 
Roback et al 
(2010) X   X       
 
Napolitano et 
al   exclude d  excluded    
Exclude
d  
 (2010)           
 Dellinger et al     NM      
 (2008)           
 
Ferraris et al 
(2007) X  X X       
 
Spahn et al 
(2007) X X X X X  X X   
 Stainsby et al     NM      
 (2006)           
 
Wong et al 
(2007)     NM      
 
Droubatchevs
kaia     NM      
 et al (2007)           
 
ASA Task 
Force     NM      
 (2006)           
 New Zealand     X X     
 (2001)           
 
Cochrane 
(2009)     NM      
(“NM “ indicates not mentioned) 
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Table 8 demonstrates the databases utilized to yield the literature searches and reviews performed by 
each working group for the eleven international guidelines. Six of the eleven guidelines utilized 
Pubmed/Medline searches and four of the eleven guidelines utilized Cochrane Central searches. One guideline 
utilized EMBASE, one guideline utilized National Library of Medicine, and another guideline utilized Current 
Contents. Four of the eleven guidelines did not reveal the types of databases utilized when performing their 
literature searches for their guideline development.  
Table 8. Systematic review: Databases Utilized 
 
 Author Medline/Pu b M ed  EMBASE Cochran e National Current  
    Central Library of Contents   
     Medicine   
 Roback et al (2010)   NM    
 Napolitano et al (2010) X X X X   
 Dellinger et al (2008) X      
 Ferraris et al (2007)   NM    
 Spahn et al (2007) X  X    
 Stainsby et al (2006) X  X    
 Wong et al (2007) X      
 Droubatchevskaia et al       
 (2007)       
 ASA Task Force (2006)   NM    
 New Zealand (2001)   NM    
 Cochrane (2009) X  X  X  
 
Methodology Utilized to Grade Evidence 
Table 9 reports the methodology utilized by the eleven guideline’s working groups to grade and rate 
evidence. Three of the eleven guidelines either utilized the Grading of Recommendations, Assessment, 
Development, and Evaluation (GRADE) methodology, or the Agency for Healthcare Research and Quality 
(AHRQ) methodology.
47-51
 The five guidelines not utilizing the GRADE or AHRQ methodologies, utilized any 
one of the following: the U.S. Preventative Task Force (USPSTF) methodology, American College of 
Cardiology/American Heart Association (ACC/AHA) methodology, Australian National Health and Medical 
Research Council (NHMRC) methodology or the American Society of Anesthesiologists (ASA) 
methodology.
52-55
 
 
Table 9. Methodology utilized by Guideline Committees to Rate Evidence 
 
Author GRADE USPSTF ACC/AH A ASA NHMRC  ARHQ Cochran e 
Roback et al (2010) X       
Napolitano et al (2010)  X      
Dellinger et al (2008) X       
Ferraris et al (2007)   X     
Spahn et al (2007) X       
Stainsby et al (2006)      X  
Wong et al (2007)      X  
Droubatchevskaia et al      X  
(2007)        
ASA Task Force (2006)    X    
New Zealand (2001)     X   
Cochrane (2009)       X 
TOTAL 3 1 1 1 1 3 1 
 
GRADE = Grading of Recommendations, Assessment, Development, and Evaluation USPSTF = U.S. 
Preventative Task Force 
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ACC/AHA = American College of Cardiology/American Heart Association ASA = American Society of 
Anesthesiologists 
 
NHMRC = Australian National Health and Medical Research Council ARHQ = Agency for Healthcare 
Research and Quality 
  
Practice Guideline Recommendations  
Table 10 and figure 3 represent the total number of recommendations made by the working gro up panel 
regarding use of blood and blood product transfusion in the perioperative setting. The total number of 
recommendations ranged from one to twenty-eight total recommendations for each of the guidelines. A total of 
107 recommendations were generated about packed red blood cells, fresh frozen plasma, platelets, and 
cryoprecipitate transfusion. Of the 107 recommendations, 48 (48.86%) of the recommendations were specific to 
the use of packed red blood cells, 31 (28.97%) of the recommendations were specific to the use of fresh frozen 
plasma, 15 (12.02%) of the recommendations were specific for the use of platelets, and only 13 (12.15%) 
recommendations were specific to the use of cryoprecipitate. (Figure 3) 
Table 10. Number of Recommendations Suggested for each Component of Blood Therapy 
 
Author Packed Red Fresh Frozen Platelets  Cryoprecipitate Total 
 Blood Cells Plasma   Regarding 
     Blood  
     Products 
Roback et al (2010) 1 6 0 0 7 
Napolitano et al 28 0 0 0 28 
(2010)      
Dellinger et al (2008) 2 1 1 0 4 
Ferraris et al (2007) 9 0 0 0 9 
Spahn et al (2007) 1 1 3 1 6 
British Columbia 1 11 7 2 21 
(2006/2007)      
ASA Task Force (2006) 2 5 3 3 8 
New Zealand (2001) 3 7 6 2 14 
Cochrane (2009) 1 0 0 0 1 
TOTAL 48/10 7 31/10 7 15/10 7 13/10 7 107/1 0 7 
 (48.86 % ) (28.97 % ) (12.02 % ) (12.15 % ) (100% ) 
 
 
Figure 3. Total Number of Recommendations   
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Of the 107 recommendations, table 11 and figure 4 demonstrate that only 12 (11.21%) 
recommendations were generated from “strong” level evidence, 25 (23.36%) recommendations were generated 
from “intermediate” level evidence, and 70 (65.42%) recommendations were generated from “low” level 
evidence. 
 
Table 11. Level of Evidence Utilized for All Blood Product Recommendations  
 
Level of Evidence Packed Red Fresh Frozen Cryoprecipitate Platelets  Number/Total (% ) 
 Blood Cells  Plasma     
STRONG 4 (8.33%) 7 (22.58%) 0 (0.00 % ) 1 (6.67%) 12/107 (11.21%) 
INTERMEDIATE 24 (50.00%) 1 (3.23%) 0 (0.00 % ) 0 (0.00%) 25/107 (23.36%) 
LOW 20 (41.67%) 23 (74.19%) 13 (100%) 14 (93.33%) 70/107 (65.42%) 
Total  48  31 13  15 107/107 (100%)  
 
Figure 4. Level of Evidence Utilized for All Blood Product Recommendations   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Of the 107 recommendations, table 12 and figure 5 demonstrate that 36 (33.64%) recommendations were 
classified as a “strong” recommendation to perform the intervention, 46 (42.99%) recommendations were 
classified as an “intermediate” recommendation to perform the intervention, and 25 (23.36%) recommendations 
were classified as a “weak” recommendation to perform the intervention. 
 
Table 12. Strength of Recommendations for All Blood Products  
 
 Strength of Packed Red Fresh Cryoprecipitate Platelets  Number/Total   
 Recommendation Blood Cells  Frozen    (% )   
   Plasma       
 STRONG 10 (20.83%) 
9 (29.03 % ) 7 (53.85 % ) 10 (66.67%) 36/107 (33.64%) 
  
     
 INTERMEDIATE 31 (64.58%) 10 (32.2 6 % ) 5 (38.46 % ) 0 (0.00%) 46/107 (42.99%)   
 WEAK 7 (14.58 % ) 12 (38.7 1 % ) 1 (7.69%) 5 (33.33%) 25/107 (23.36%)   
 Total 48 31 13  15 107/1 07 (100% )   
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Figure 5. Strength of Recommendations for All Blood Products   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Recommendations Regarding Clinical Use of Red Blood Cells  
 
Table 10 demonstrates that a total of 48 of the 107 recommendations were relevant to  packed red blood 
cell use. Of the 48 recommendations, table 11 and figure 6 demonstrate that 4 (8.33%) recommendations were 
generated from “strong” level of evidence, 24 (50.00%) recommendations were generated by “intermediate” 
level evidence, and 20 (41.67%) recommendations were generated by “low” level evidence.  
Figure 6. Level of Evidence Utilized for Packed Red Blood Cell Recommendations   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Of the 48 recommendations, table 12 and figure 7 demonstrate that 10 (20.83%) recommendatio ns 
were classified as a “strong” recommendation to perform the intervention, 31 (64.58%) recommendations were 
classified as an “intermediate” recommendation to perform the intervention, and 7 (14.58%) recommendations 
were classified as a “weak” recommendation to perform the intervention. Of the 10 “strong” recommendations, 
1 (10.00%) recommendation was based on “strong” level of evidence, 3 (30.00%) recommendations based on 
“intermediate” level of evidence, and 6 (60.00%) recommendations based on “low” leve l of evidence (Figure 8). 
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Figure 7. Strength of Recommendations for Packed Red Blood Cells   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Level of Evidence for “Strong” Recommendations regarding use of RBC  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix table 1 summarizes the eleven 
international guideline recommendations for the 
clinical use of packed red blood cells. Of the 
guidelines reviewed, 7 of 10 international 
guidelines have commented on the indications and 
utilization of packed red blood cells. A target Hb 
level of 7-9g/dL is recommended (Dellinger, Level 
1B; Spahn, Grace 1C) 
51,56
, but other target ranges 
such as Hb 6-10g/dL (ASA, strongly) or 7-10g/dL 
(Australia, Level IV) has also been recommended 
as well. 
51,54-56 
 
Five guidelines stated RBC should be 
administered when the hemoglobin level is <7g/dL 
(Table 13). Napolitano et al recommended 
consideration of transfusion with a Hb <7g/dL in 
critically ill patients with acute hemorrhage, with 
hemodynamic instability, with inadequate oxygen 
delivery (Level 1), requiring mechanical ventilation 
or resuscitated critically ill trauma and stable 
cardiac patients without acute myocardial ischemia 
(Level 2), and Ferraris et al stated it was 
reasonable for transfusion with a Hb <7g/dL in 
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most post-operative patients (Class 2A, C), and not 
unreasonable for patients on cardiopulmonary 
bypass with risk for critical end-organ 
ischemia/injury (Class 2B, C). 
 
52,53
 Dellinger et al strongly recommended the 
threshold for giving RBC be Hb<7g/dL with a 
target hemoglobin of 7-9g/dL in adults. They also 
suggested that a higher hemoglobin level may be 
required in the setting of myocardial ischemia, 
severe hypoxemia, acute hemorrhage, cyanotic 
heart disease, or lactic acidosis in patients  
(Level 1B, Strong). 
56
 
 
Table 13. Guidelines recommending transfusion threshold of Hb <7 g/dL 
 
Organization Recommendation Evidence 
Napolitano (USPTF) Level 1 (convincingly justifiable Class 1, Class 2 (Prospective 
 based on scientific evidence) RCT, strong prospective and 
 Level 2 (reasonable scientific retrospective analysis) 
 evidence and strong expert opinion) Class 2, Class 3 (Strong 
  prospective and retrospective 
  analysis, retrospective data 
  collection) 
Dellinger (GRADE) Strong / Grade 1 (Recommend; Class B (Moderate; RCT with 
 benefits do or do not outweigh important limitations or very 
 harm and burden) strong evidence from 
  observational studies or case 
  series) 
Ferraris (ACC/AHA) Class 2B (Usefulness/efficacy is less  Level C (Consensus opinions of 
 well established by experts) 
 evidence/opinion)  
New Zealand (NHMRC) - Level IV (Evidence obtained 
  from case series, either post- 
  test or pretest and post-test)  
 
In Table 14 Napolitano et al suggested that a transfusion threshold of Hb </= 8g/dL may be beneficial 
in patients with acute coronary syndromes who are anaemic on hospital admissions (Level 3).
52
 More 
“restrictive” hemoglobin transfusion triggers were recommended by several guidelines.  
 
Table 14. Guidelines recommending transfusion threshold of Hb </= 8g/dL 
 
Organization Recommendation Evidence 
Napolitano (USPTF) 
Level 3 (Supported by data but 
lacking Class 3 (retrospective data 
 adequate scientific evidence) collection) 
British Columbia (AHCPR) Grade C (Absence of directly Level IV (Evidence from expert 
 applicable clinical studies of good committee reports or opinions  
 quality) and/or clinical experiences of 
  respected authorities) 
In Table 15 Ferraris et al stated that for hemoglobin levels <6g/dL, transfusion with RBC is reasonable 
and can be life-saving (Class 2A, C), reasonable and life-saving for cardiac operations (Class 2A, C), 
reasonable during cardiopulmonary bypass withmoderate hypothermia except in patients at risk for decreased 
cerebral oxygen delivery, such as those with histories of cardiovascular disease, diabetes mellitus, 
cerebrovascular disease, and carotid stenosis (Class 2A, C), and additionally the ASA Task Force strongly 
agreed upon in the setting of a young, healthy patient especially when the anemia is acute and without low 
cardiopulmonary reserve and high oxygen consumption 
(strongly). 
53,54
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Table 15. Guidelines recommending transfusion threshold of Hb <6 g/dL 
 
Organization Recommendation Evidence 
Ferraris (ACC/AHA) 
Class 2A (weight of evidence/opinion 
is C (consensus opinions of experts) 
 in favor of usefulness/efficacy)  
British Columbia (AHCPR) 
Grade C (absence of directly 
applicable Level IV (evidence from expert 
 clinical studies of good quality) committee reports or opinions  
  and/or clinical experiences of 
  respected authorities) 
ASA Strongly agree Insufficient 
 
In Table 16 four guidelines did not 
support the use of 10g/dL as a hemoglobin 
transfusion trigger for RBC. Napolitano et al stated 
there is no benefit of a “liberal” transfusion when 
Hb >10g/dL in critically ill patients on mechanical 
ventilation, resuscitated critically ill trauma 
patients, critically ill patients with stable cardiac 
disease, or in patients with moderate to severe 
traumatic brain injury (Level 2). 
52
 The ASA Task 
Force strongly agreed that RBC are usually 
unnecessary when the hemoglobin level is more 
than 10g/dL (strongly), Stainsby et al stated it was 
rarely indicated when Hb >10g/dL (Level 1), and 
the Australian guideline stated that it is likely 
inappropriate to transfuse at that hemoglobin 
level unless there are specific indications (Level I). 
47,54,55
 However, Ferraris et al stated that it is not 
unreasonable to transfuse red cells in certain 
patients with clinical non-cardiac end-organ 
ischemia, such as the central nervous and 
gastrointestinal system, whose hemoglobin level is 
as high as 10g/dL (Class 2B, C). 
53
 However this 
statement was modified with the disclaimer that 
such a “liberal transfusion” it is unlikely to 
improve oxygen transport and is not 
recommended for those purposes (Class  2B, C). 
53
 
Practice Guideline Recommendations  
Almost half (48.86%) of the total 
recommendations reviewed pertain only to the 
transfusion of packed red blood cells (Table 10 and 
figure 3). The rest of the recommendations 
reviewed pertain to coagulation blood components 
such as fresh frozen plasma (28.97%), platelets 
(12.02%), and cryoprecipitate (12.15%). This 
suggests that there is mounting literature regarding 
the transfusion of packed red blood cells, but 
substantial evidence is still lacking regarding the 
appropriate use and safety of fresh frozen plasma, 
platelets, and cryoprecipitate. 
Of the 107 recommendations reviewed, a 
majority (65.42%) of the recommendations were 
based from “low” level of evidence. This “low” 
level of evidence may include case series or 
reports, expert reports or opinions, and evidence 
that is limited in power or demonstrates flaws in 
the study design. Only 12 (11.21%) 
recommendations are based on “strong” level of 
evidence, such as meta-analyses and randomized 
controlled trials. Our analysis suggests the lack of 
relationship/association between the quality of 
evidence reviewed and the strength of 
recommendations generated by the guideline 
working panels (Table 11, Table 12, Figure 4, 
Figure 5). Though 82 (76.63%) recommendations 
are classified as “strong” or “intermediate” 
recommendations, they are based solely on “low” 
level of evidence (Table 12, Figure 5). 
Recommendations Regarding Clinical Use of 
Blood Products  
A majority (85.41%) of recommendations 
for packed red blood cells deemed as “strong” and 
“intermediate” are based almost entirely (91.67%) 
on “intermediate” and “low” level of evidence. Of 
the “strong” recommendations regarding the use of 
packed red blood cells, majority were based on a 
“low” level of evidence. More than half (61.29%) 
of recommendations for fresh frozen plasma 
deemed “strong” and “intermediate” are based 
exclusively (74.19%) on “low” level of evidence. 
All recommendations pertaining to cryoprecipitate 
transfusion are based solely on “low” level of 
evidence. A majority of “strong” recommendations 
for platelet transfusion are based almost entirely 
(93.33%) on “low” level evidence. With the slight 
exception of packed red blood cells, all guidelines 
undividedly reported “strong” and/or 
“intermediate” recommendations to transfuse 
coagulation products on the basis of “low” level 
evidence. 
In addition, there was multiple 
hemoglobin level transfusion triggers are reported 
amongst the eleven guidelines, and even within a 
guideline. There was clearly a discrepancy between 
guideline recommendations about transfusing for a 
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particular hemoglobin level, as well as, a 
discrepancy between the quality and strength of 
evidence to support the recommendation. For 
example in regard to use of 6g/dL of hemoglobin as 
a packed red blood cell transfusion trigger, the two 
organizations utilized the same quality of evidence 
(consensus opinions of experts) yet generated 
different recommendations. One organization 
favored the use and efficacy of the intervention, 
while the other organization gave the intervention 
its lowest level of recommendation.
53,54
 
In addition, one organization reported two different 
hemoglobin levels as transfusion triggers in the 
context of different clinical settings.
53
 both 
recommendation statements were based on 
“consensus opinions of experts.” The 
recommendation to transfuse at hemoglobin < 
6g/dL is graded Class 2A supporting the 
intervention in favor of its usefulness and efficacy, 
whereas the recommendation to transfuse at 
haemoglobin 7g/dL is graded Class 2B giving 
weaker support to the recommendation as the 
usefulness and efficacy. It is unclear through 
analysis of these eleven guidelines what specific 
hemoglobin level should be utilized as the 
threshold hemoglobin level to trigger transfusion of 
packed red blood cells. The only consensus is not 
to transfuse if the Hb is > 10gm/dl. 
The recommendations generated for the 
use of fresh frozen plasma, platelets, and 
cryoprecipitate are based on even weaker level of 
evidence compared to the recommendations 
generated for use of packed red blood cells. The 
recommendations for coagulation products are 
insufficient, both in number of total 
recommendations and in strength of 
recommendations. Two organizations have stated a 
definite threshold to transfuse fresh frozen plasma 
(PT or aPTT is > 1.5 normal). 
58,61
 However, the 
data come from the same quality of evidence (case 
series, observational studies, and consensus opinion 
of experts). In the eleven guidelines we evaluated, 
there is no consensus regarding a definite platelet 
level or a fibrinogen which should trigger 
transfusion. 
Limitations of Study 
The following are the limitations of this 
investigation. Of the guidelines included, only 
guidelines published in the English language were 
reviewed, as well as, only guidelines published in 
the last ten years were reviewed. We have only 
reviewed guidelines relevant to adult patients. In 
addition, only two reviewers screened the initial 
literature searches performed on PubMed/Medline, 
Scopus, Cochrane Central and the National 
Guideline Clearinghouse, and determined that the 
final eleven guidelines to be selected for inclusion 
in the study. 
In order to compare different guidelines 
we had to develop a uniform scoring system. These 
definitions were created to readily compare the 
eleven guidelines that had all used different grading 
and classification methodology systems. However, 
this scoring system has not been externally 
validated and is kind of unique. However we feel 
that the system is valid as it generally encompasses  
and closely follows the definitions that were used 
by the original seven methodologies. 
Implications of Study 
Analysis of these eleven international 
guidelines suggests that currently a large body of 
recommendations concerning blood component 
therapy is based solely on “low” quality evidence. 
Clearly there is a significant scarcity of strong 
evidence as well as clearly explicit 
recommendations to guide clinician practice of 
transfusion of blood products. In addition, many of 
the guidelines are not clear in reporting their 
methods of literature search, working group 
composition, and evidence review process. There is 
also a lack of consistency in current guidelines’ use 
of evidence grading methodologies. This adds 
confusion to the interpretation of the 
recommendations generated for clinicians and 
applications of guidelines. 
The use of different grading 
methodologies generates discrepancies in 
recommendations. The use of multiple and 
different grading methodologies does not allow for 
clinicians to readily compare recommendations 
generated from guidelines. In addition, each 
methodology systems assigns quality of evidence 
based on a variety of factors and thus can result in 
varying strength of recommendations for the same 
intervention even though derived from the similar 
data. These multiple recommendations with 
varying strengths from guidelines can translate to 
inconsistencies in practices amongst practitioners. 
This study demonstrates that there currently is lack 
of robust and methodologically clear transfusion 
guidelines. Quality randomized controlled trials 
should be conducted especially with regards to the 
appropriate use and safety of fresh frozen plasma, 
cryoprecipitate and platelets. In addition, the use of 
multiple evidence grading methodologies creates  
discrepancies in recommendations and confusion 
amongst clinicians. Under these circumstances, it 
seems logical that future directions with guideline 
development should be aimed at the utilization of a 
universal methodology system to grade evidence 
and classify recommendations. Moreover, there 
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should be more integration of surgical subspecialty 
physicians in working group panels in the 
development of guideline recommendations. In 
conclusion, future research should also be 
stimulated and directed at providing more abundant 
and high quality evidence regarding the use and 
safety of blood components in the perioperative 
setting. 
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